Valuation: Bolt Biotherapeutics, Inc.

Market Cap 6.28M 5.38M 5.02M 4.6M 8.65M 601M 8.82M 59.51M 23.2M 301M 23.58M 23.07M 997M P/E 2026 *
-0.14x
P/E 2027 * -0.16x
Enterprise Value 6.28M 5.38M 5.02M 4.6M 8.65M 601M 8.82M 59.51M 23.2M 301M 23.58M 23.07M 997M EV / Sales 2026 *
31.4x
EV / Sales 2027 * 1.79x
Free-Float
96.53%
Yield 2026 *
-
Yield 2027 * -
1 day-2.45%
1 week-0.93%
Current month-20.30%
1 month-28.94%
3 months-31.02%
6 months-37.03%
Current year-41.84%
1 week 3.16
Extreme 3.16
3.74
1 month 3.13
Extreme 3.13
4.34
Current year 3.13
Extreme 3.13
7.2
1 year 3.13
Extreme 3.13
7.2
3 years 3.13
Extreme 3.13
31.2
5 years 3.13
Extreme 3.13
385.7
10 years 3.13
Extreme 3.13
861.4
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 14/05/2024
Chief Executive Officer 55 14/05/2024
Chief Operating Officer 61 14/05/2024
Director TitleAgeSince
Director/Board Member 64 30/11/2020
Director/Board Member 55 14/05/2024
Chairman 56 03/09/2024
Date Insider Type Main position Quantity % Market Cap.
10/06/26 Free

Chairman

5,000 0.2602%
28/01/26 Free

Chief Operating Officer

10,000 0.5210%
28/01/26 Buy

Chief Executive Officer

20,125 1.0485%
Change 5-day change 1-year change 3-year change Capi.($)
-2.45%-0.93%-34.84%-86.17% 6.28M
+2.38%+5.57%+86.02%+115.89% 72.21B
+0.87%+17.34%+57.17%+94.08% 63.98B
-4.03%-0.59%-2.99%+470.82% 28.53B
+3.63%+8.62%+66.69%+23.95% 25.07B
-1.63%+20.97%+0.13%-5.18% 28.42B
-0.51%+5.73%+38.71%-14.19% 20.04B
-1.79%-4.51%+241.26%+414.48% 18.19B
+1.81%+0.85%+16.89%+546.06% 15.96B
-1.29%+6.34%+42.16%+151.85% 13.48B
Average -0.32%+4.51%+51.12%+171.16% 28.59B
Weighted average by Cap. +0.43%+7.48%+61.08%+161.93%

Financials

2026 *2027 *
Net sales 200K 171K 160K 147K 275K 19.14M 281K 1.9M 739K 9.59M 751K 735K 31.75M 3.5M 3M 2.8M 2.57M 4.82M 335M 4.92M 33.17M 12.93M 168M 13.14M 12.86M 556M
Net income -47.4M -40.58M -37.87M -34.75M -65.29M -4.54B -66.57M -449M -175M -2.27B -178M -174M -7.53B -47.5M -40.67M -37.95M -34.82M -65.43M -4.55B -66.71M -450M -175M -2.28B -178M -174M -7.54B
Net Debt - -
Logo Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Employees
23
Date Price Change Volume
20/08/26 US$3.180 -2.45% 13,620
19/08/26 US$3.260 +2.60% 21,148
18/08/26 US$3.177 -0.71% 7,335
17/08/26 US$3.200 -4.48% 24,576
14/08/26 US$3.350 +4.36% 15,961
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
3.260USD
Average target price
29.00USD
Spread / Average Target
+789.57%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BOLT Stock